Kursprognose für enGene Therapeutics Inc (ENGN)ENGNenGene Therapeutics Inc

Alphio's ENGN stock price prediction model matches the current enGene Therapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $1.65 (-1.62%). The 1-week path is $1.65 (-1.88%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

enGene Holdings Inc is not a good buy right now due to significant financial losses and negative analyst sentiment. The current price is $1.45, which is 88.2% below its 52-week high of $12.25, indicating a substantial decline. Additionally, the RSI is at 23.7, suggesting the stock is oversold, but this could reflect ongoing issues rather than a buying opportunity. The company reported a net loss of $30.23 million in Q2 2026, which is wider than the previous year's loss, and its forward P/E ratio is 0, indicating no expected earnings growth. The main risk is the recent downgrade by Morgan Stanley, which has reduced its price target to $1, reflecting low confidence in the company's future performance.

enGene Therapeutics Inc (ENGN) last closed at $1.6799999, losing -2.33%. These facts feed the 1-day and 1-week ENGN price prediction above.